Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06606340 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice

Name: A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice — clinical trial record (NCT06606340)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: EVOLVE

StatusEnrolling by Invitation

PhaseNot specified

SponsorSarepta Therapeutics, Inc.

Started2019-01-07

View on ClinicalTrials.gov ↗

Amendment history

2025-09-03

Study Status v1

Re-verified, no change to tracked fields

2024-09-19

Original filing

Sarepta Therapeutics, Inc.

14 trials monitored

See 3 trials at risk

Duchenne Muscular Dystrophy

156 trials monitored

See 6 trials at risk

This is a phase 4, multicenter, prospective, observational study designed to collect both medical history data and prospective data on Duchenne Muscular Dystrophy (DMD) treatment outcomes in participants receiving eteplirsen, golodirsen, and casimersen in routine clinical practice. Participants in this study will have been prescribed eteplirsen, golodirsen, or casimersen commercially prior to entry into the study.

Trial Details

NCT Number	NCT06606340
Lead Sponsor	Sarepta Therapeutics, Inc.
Conditions	Duchenne Muscular Dystrophy
Enrollment	300 participants
Start Date	2019-01-07
Primary Completion	2033-12-31 (estimated)
Study Completion	2033-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-09-10